Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sommadossi

Showing results (171-180 of 175) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 175 results.
The Journal of Infectious Diseases|May 1, 1997
Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study GroupR J Whitley, G Cloud, W Gruber, et al.
Nature Communications|February 3, 2022
A dual mechanism of action of AT-527 against SARS-CoV-2 polymeraseAshleigh Shannon, Véronique Fattorini, Bhawna Sama, et al.
Antiviral Research|March 11, 2023
AT-752 targets multiple sites and activities on the Dengue virus replication enzyme NS5Mikael Feracci, Cécilia Eydoux, Véronique Fattorini, et al.
Antiviral Chemistry & Chemotherapy|October 3, 2007
2'-C-Methyl branched pyrimidine ribonucleoside analogues: potent inhibitors of RNA virus replicationSamira Benzaria, Dorothée Bardiot, Tony Bouisset, et al.
AIDS (London, England)|April 18, 2003
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patientsRemko van Leeuwen, Christine Katlama, Robert L Murphy, et al.
Pageof 18

Showing results (171-180 of 175) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 175 results.
The Journal of Infectious Diseases|May 1, 1997
Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study GroupR J Whitley, G Cloud, W Gruber, et al.
Nature Communications|February 3, 2022
A dual mechanism of action of AT-527 against SARS-CoV-2 polymeraseAshleigh Shannon, Véronique Fattorini, Bhawna Sama, et al.
Antiviral Research|March 11, 2023
AT-752 targets multiple sites and activities on the Dengue virus replication enzyme NS5Mikael Feracci, Cécilia Eydoux, Véronique Fattorini, et al.
Antiviral Chemistry & Chemotherapy|October 3, 2007
2'-C-Methyl branched pyrimidine ribonucleoside analogues: potent inhibitors of RNA virus replicationSamira Benzaria, Dorothée Bardiot, Tony Bouisset, et al.
AIDS (London, England)|April 18, 2003
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patientsRemko van Leeuwen, Christine Katlama, Robert L Murphy, et al.
Pageof 18